What Is Covid 19 Journal Article

Open Access This article is licensed under a Creative Commons Attribution 4.0 International license, which allows the use, distribution, adaptation, distribution, and reproduction on any medium or format, provided that the original author(s) and source are properly mentioned, provide a link to the Creative Commons license, and indicate whether any changes have been made. Images or other third-party materials contained in this article are included in the Article`s Creative Commons License, unless otherwise specified in a line of credit for the material. If the material is not included in the creative commons license of the article and your intended use is not permitted by law or exceeds the permitted use, you must obtain permission directly from the copyright owner. A copy of this license can be found on creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication (creativecommons.org/publicdomain/zero/1.0/) waiver applies to the data provided in this article, unless otherwise specified in a line of credit for the data. Suliman Khan received his Ph.D. from the Chinese Academy of Sciences and is currently working as a postdoctoral fellow at the second affiliated hospital of Zhengzhou University. He has published more than 25 and 5 articles on SARS-CoV-2 in prestigious journals, including Clinical microbiology and infection (CMI) and Journal of clinical microbiology (ASM-JCM) first and accordingly. Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, et al. The outbreaks of SARS, MERS and novel coronavirus (COVID-19), the most recent and significant threats to global health: what lessons have we learned? International Journal of Epidemiology. 2020.

Other reviews (most have made covid-19 articles open access or free while the pandemic continues): We conducted a descriptive analysis of the characteristics of the included literature. We have described the source where we found the article, the date of publication, the type of article/study and the topic of the article/study or orientations/policies on COVID-19 to explore existing research gaps. We classified the literature into guidelines/guidelines and consensus statements, reviews, clinical trials (including randomised controlled trials and observational studies), basic research, epidemiological studies, editorial comments on COVID-19 and other categories if identified. We conducted this scoping review in accordance with the PRISMA-ScR checklist [16] (Supplementary Table S3). Of the 249 articles/studies included, 147 (59.0%) were from China. The type of article/study varied considerably, which we roughly divided into 11 types (Table 1). Of these, guidelines/guidelines and consensus statements were the most prevalent (n = 56; 22.5%). Muhammad Adnan Shereen is a PhD student at Wuhan University and works on Zika virus and coronavirus in the areas of pathogenesis, drug screening and molecular mechanisms. He is the author of 8 articles published in journals with an impact factor of more than 5, including the recently adopted work in Nature microbiology.

The research topics in different types of articles/studies had both similarities and differences. Basic research has mainly focused on studying the origin and reservoirs of the new virus, while epidemiological studies have focused mainly on its transmissibility. Reviews and reports provided more general information about the virus and the outbreak, while guidelines included recommendations for prevention and control. We have included all COVID-19 literature published without restriction in English and Chinese between December 1, 2019 and February 6, 2020, including guidelines/guidelines, reviews, clinical trials, basic research, epidemiological studies, and commentary. Documents and guidelines issued by international organizations, government institutions, associations and corporations were also included. We excluded reports that were not published in scientific journals and articles where we could not access the full text despite contact with the authors. We conducted a COVID-19 scoping review and conducted extensive searches of databases and other sources to identify the COVID-19 literature between December 1, 2019 and February 6, 2020. We analysed the sources, date of publication, type and subject of the articles/studies retrieved.

Of all included articles and studies, 192 (77.1%) were published in peer-reviewed journals, 35 (14.1%) were published on preprint servers, and 22 (8.8%) were published on the official websites of public health agencies. The journal with the highest number of articles was The Lancet with 13 (6.8%) articles published. Of the preprinted articles, most (n = 28) were published on BioRxiv. The articles published on the Official websites were mainly COVID-19 guidelines, including 10 preliminary WHO guides, nine US CDC preliminary guidelines/guidelines, two ECDC guidelines and one directive from the Communicable Diseases Network Australia (CNDA). The types of articles/studies published each day are shown in Figure 3. The daily number of guidelines peaked between January 29 and February 3, while the number of notices published has shown an upward trend since January 29, 2020. Only one systematic review was identified [17]. We found no randomised controlled trials or cohort studies. The WHO [6-9], the US Centers for Disease Control and Prevention (CDC) [10,11], the European Centre for Disease Prevention and Control (ECDC) [12,13] and Chinese researchers have published several guides or guidelines to help control outbreaks.

Meanwhile, many scientific journals have quickly published a number of articles, commentaries, editorials, and perspectives related to COVID-19. However, it can be difficult for the global research community to find all the available evidence: many of the early COVID-19 studies were published in Chinese, and due to the rapidly changing situation, the latest studies are often only available on websites or preprint servers [14]. Two reviewers (ML and XL) reviewed all titles, abstracts and complete texts independently of each other and resolved disagreements by consensus or consultation with a third reviewer. Next, the following information was extracted: (i) title, (ii) first author, (iii) peer-reviewed or not, (iv) journal, (v) date of publication or publication, (vi) country (or international organization) of the first author, (vii) type of article/study, and (viii) subject. Details are given in Supplementary Table S2. This study also has some limitations. Due to the delay in indexing, some articles published on February 6, 2020 may not have been identified. Since our recovery time was only up to that date, the articles published or published after that date, which were numerous, were not included in the analysis. Since some preprints, guidelines, and disease control plans are constantly updated, the release date we extract may not be the time of their first publication.

.

Запись опубликована автором в рубрике Без рубрики.